Taysha Gene Therapies, Inc. (TSHA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Taysha Gene Therapies, Inc. (TSHA) Healthcare & Pipeline Overview

Taysha Gene Therapies, Inc. is a Dallas-based biotechnology company specializing in adeno-associated virus (AAV) gene therapies for rare monogenic central nervous system diseases. Leveraging a strategic partnership with UT Southwestern Medical Center, the company advances a pipeline of candidates, including TSHA-120 for giant axonal neuropathy and TSHA-102 for Rett syndrome, addressing significant unmet medical needs.

What Is the Investment Thesis for TSHA?

Taysha Gene Therapies, Inc. presents a research-grade thesis centered on its specialized focus within the high-potential gene therapy sector, specifically targeting rare monogenic central nervous system diseases. The company's value drivers include a broad pipeline of AAV-based gene therapies, such as TSHA-120 for giant axonal neuropathy and TSHA-102 for Rett syndrome, each addressing conditions with significant unmet medical needs and orphan drug potential. The strategic partnership with The University of Texas Southwestern Medical Center provides a foundational advantage in research and development, potentially accelerating clinical progress and expanding intellectual property. Financially, Taysha operates with a market capitalization of $1.95B and a gross margin of 100.0%, typical for a pre-commercial biotechnology company. However, its Return on Equity (ROE) stands at -97.3%, reflecting substantial R&D investments prior to revenue generation. The debt-to-equity ratio is 32.34, and its Beta is 1.23, indicating higher volatility relative to the broader market. Key growth catalysts are anticipated clinical trial readouts for its lead programs and potential regulatory milestones. The inherent risks include the high failure rate of clinical trials, substantial capital requirements for ongoing R&D, and intense competition within the gene therapy landscape. Success hinges on positive clinical data and subsequent regulatory approvals.

Based on FMP financials and quantitative analysis

TSHA Key Highlights

Market capitalization stands at $1.37 billion, reflecting investor valuation in the specialized gene therapy sector.

• Achieved a gross margin of 100.0%, characteristic of a pre-commercial biotechnology company focused on research and development.
• Reported a Return on Equity (ROE) of -97.3%, indicative of significant investment in R&D and clinical trials prior to product commercialization.
• Maintains a debt-to-equity ratio of 32.34, suggesting a moderate reliance on debt financing for its operations and development activities.
• Specializes in developing adeno-associated virus (AAV)-based gene therapies specifically for monogenic diseases of the central nervous system, addressing rare and severe conditions.

Who Are TSHA's Competitors?

TSHA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TSHA's Key Strengths?

Specialized focus on AAV gene therapies for monogenic CNS diseases, addressing high unmet medical needs.

• Diverse pipeline with multiple candidates targeting different rare neurological disorders.
• Strategic partnership with The University of Texas Southwestern Medical Center, providing research and development advantages.
• Gross margin of 100.0%, typical for a pre-commercial biotech, indicating no cost of goods sold currently.
• Experienced leadership in the biotechnology sector.

What Are TSHA's Weaknesses?

Currently a pre-revenue company, reliant on external funding for operations and R&D.

• Negative Return on Equity (-97.3%) reflecting significant investment without commercial products.
• High inherent risks associated with clinical trial failures, delays, or unexpected adverse events.
• Significant capital requirements for ongoing research, development, and potential commercialization.
• Limited operational history as the company was incorporated in 2019.

What Could Drive TSHA Stock Higher?

TSHA catalyst: Anticipated clinical data readouts for TSHA-120 in giant axonal neuropathy, which could provide critical insights into the therapy's efficacy and safety profile.

• Potential regulatory interactions and updates regarding the clinical development pathway for TSHA-102 in Rett syndrome, signaling progress towards potential marketing applications.
• Initiation of new clinical trials or expansion of existing trials for pipeline candidates like TSHA-121 or TSHA-118 for CLN1 disease, demonstrating pipeline advancement.
• Continued progress in the strategic partnership with The University of Texas Southwestern Medical Center, potentially leading to new pipeline candidates or enhanced technological capabilities.

What Are the Key Risks for TSHA?

Negative return on equity (-56.2%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays across any of its pipeline candidates, particularly TSHA-120 or TSHA-102, which could significantly impact the company's valuation and future prospects.
• High capital requirements for research and development, necessitating continuous access to funding, which could lead to further equity dilution.
• Regulatory approval uncertainties, as gene therapies face rigorous scrutiny from health authorities, and approval is not guaranteed even with positive clinical data.
• Intense competition within the gene therapy space for rare CNS diseases, with other companies potentially developing similar or more advanced therapies.
• Intellectual property challenges, including the risk of patent infringement claims or the inability to secure broad patent protection for its gene therapy technologies.

What Are the Growth Opportunities for TSHA?

• Growth opportunity 1: Advancement of TSHA-120 for Giant Axonal Neuropathy (GAN). TSHA-120 is a lead candidate targeting GAN, a rare, severe, and progressive genetic disorder affecting the peripheral and central nervous systems. There is a significant unmet medical need for effective treatments for GAN, which currently has no approved disease-modifying therapies. Successful clinical development and potential regulatory approval of TSHA-120 could unlock a substantial market opportunity within the orphan disease space, where therapies often command premium pricing due to the small patient population and high development costs. The timeline for this opportunity is tied to ongoing clinical trial progress and subsequent regulatory filings, potentially within the next 3-5 years, assuming positive data.
• Growth opportunity 2: Development of TSHA-102 for Rett Syndrome. TSHA-102 is being developed for Rett syndrome, a severe neurodevelopmental disorder that primarily affects girls, leading to profound intellectual and physical disabilities. The global prevalence of Rett syndrome is estimated to be around 1 in 10,000 to 1 in 23,000 live female births, representing a significant patient population within the rare disease category. A successful gene therapy for Rett syndrome could offer a transformative treatment option, addressing a critical unmet need. The market potential is substantial, given the chronic nature of the disease and the profound impact on patients and caregivers. Clinical milestones and regulatory pathways over the next 3-6 years will be crucial for realizing this opportunity.
• Growth opportunity 3: Expansion of pipeline for CLN1 Disease with TSHA-121 and TSHA-118. Taysha is developing two distinct candidates, TSHA-121 and TSHA-118, for CLN1 disease, a devastating lysosomal storage disorder also known as infantile neuronal ceroid lipofuscinosis. This dual approach may allow for targeting different aspects or stages of the disease, or for different patient populations, thereby broadening the potential market reach within this specific indication. The prevalence of CLN1 disease is extremely rare, but the severity of the condition underscores the urgent need for effective therapies. Successful development of either or both candidates would solidify Taysha's position in treating ultra-rare neurological disorders, with potential regulatory approvals anticipated in the mid to late 2020s.
• Growth opportunity 4: Leveraging the strategic partnership with The University of Texas Southwestern Medical Center. This collaboration provides Taysha with access to a robust pipeline of gene therapy programs and cutting-edge research capabilities. The partnership acts as a continuous source of novel therapeutic candidates and scientific expertise, potentially reducing internal R&D costs and accelerating discovery. This ongoing relationship can lead to the identification of new targets, optimization of AAV vectors, and expansion into additional monogenic CNS diseases. The long-term value of this partnership lies in its ability to sustain Taysha's innovation engine and maintain a competitive edge in a rapidly advancing scientific field, contributing to pipeline growth over the next 5-10 years.
• Growth opportunity 5: Addressing other monogenic CNS diseases, including SLC13A5 Deficiency and GM2 gangliosidosis. Beyond its lead programs, Taysha is also developing TSHA-105 for SLC13A5 Deficiency and TSHA-101 for GM2 gangliosidosis. These programs represent further diversification within the rare monogenic CNS disease space. Successfully advancing these candidates through preclinical and clinical stages would demonstrate the versatility of Taysha's AAV gene therapy platform and expand its addressable market. Each of these conditions, while individually rare, collectively represents a significant opportunity for a company specialized in orphan diseases. Progression of these programs through early clinical phases is expected in the late 2020s, paving the way for future market entries.

What Opportunities Does TSHA Have?

• Successful clinical trial outcomes leading to regulatory approvals and market entry for lead candidates like TSHA-120 and TSHA-102.
• Expansion of the pipeline through internal research or new collaborations, targeting additional rare CNS diseases.
• Potential for orphan drug designations and accelerated regulatory pathways due to the severe nature of targeted diseases.
• Advancements in gene therapy technology and manufacturing processes to improve efficacy and reduce costs.
• Geographic expansion into international markets upon successful product commercialization in the U.S.

What Threats Does TSHA Face?

• Clinical trial failures, including lack of efficacy or unacceptable safety profiles, which could halt development.
• Intense competition from other biotechnology and pharmaceutical companies developing similar or alternative therapies.
• Regulatory hurdles, including stringent approval processes and potential delays from health authorities.
• Intellectual property disputes or challenges to patent validity from competitors.
• Funding challenges, including the ability to raise sufficient capital to support long-term R&D and commercialization efforts.

What Are TSHA's Competitive Advantages?

• Specialized AAV Gene Therapy Platform: Focus on adeno-associated virus (AAV) vectors for CNS delivery, a highly specialized and technically challenging area.
• Targeting Orphan Diseases: Development of therapies for rare monogenic CNS diseases often qualifies for orphan drug designations, providing market exclusivity and regulatory incentives.
• Strategic Partnership with UT Southwestern: Exclusive access to cutting-edge research, intellectual property, and scientific expertise from a leading academic institution.
• Proprietary Pipeline: Development of multiple distinct gene therapy candidates for various rare neurological disorders, creating a portfolio of potential future products.
• Intellectual Property: Accumulation of patents and proprietary know-how related to AAV vector design, gene constructs, and manufacturing processes for CNS gene therapies.

What Does TSHA Do?

Taysha Gene Therapies, Inc., incorporated in 2019 and headquartered in Dallas, Texas, is a clinical-stage gene therapy company dedicated to the development and commercialization of novel adeno-associated virus (AAV)-based gene therapies. The company's core focus lies in addressing monogenic diseases that primarily affect the central nervous system (CNS), a therapeutic area characterized by high unmet medical needs and often devastating patient outcomes. Taysha's approach involves delivering functional genes to target cells using AAV vectors, aiming to correct the underlying genetic defects responsible for these severe neurological disorders. The company's robust pipeline targets a range of rare and debilitating conditions. Key programs include TSHA-120, which is under development for the treatment of giant axonal neuropathy (GAN), a severe inherited neurological disorder. Another significant program is TSHA-102, designed to treat Rett syndrome, a neurodevelopmental disorder predominantly affecting females. Furthermore, Taysha is advancing TSHA-121 and TSHA-118 for the treatment of CLN1 disease, a form of neuronal ceroid lipofuscinosis. The pipeline also extends to TSHA-105 for SLC13A5 Deficiency and TSHA-101 for GM2 gangliosidosis, further diversifying its therapeutic reach within the rare CNS disease landscape. Taysha Gene Therapies has established a strategic partnership with The University of Texas Southwestern Medical Center, a collaboration designed to accelerate the development and potential commercialization of transformative gene therapy treatments. This partnership provides access to cutting-edge research, scientific expertise, and potentially novel AAV technologies, reinforcing Taysha's capabilities in gene therapy innovation. With 73 employees, the company is structured to advance its clinical programs and expand its research efforts in this specialized field.

What Products and Services Does TSHA Offer?

• Develops adeno-associated virus (AAV)-based gene therapies.
• Focuses on treating monogenic diseases of the central nervous system (CNS).
• Advances TSHA-120 for the treatment of giant axonal neuropathy (GAN).
• Develops TSHA-102 for the treatment of Rett syndrome.
• Works on TSHA-121 and TSHA-118 for the treatment of CLN1 disease.
• Explores TSHA-105 for SLC13A5 Deficiency.
• Advances TSHA-101 for the treatment of GM2 gangliosidosis.
• Engages in a strategic partnership with The University of Texas Southwestern Medical Center for gene therapy development.

How Does TSHA Make Money?

• Primarily operates as a research and development-focused biotechnology company, investing heavily in preclinical and clinical studies.
• Aims to develop and commercialize proprietary AAV-based gene therapies for rare monogenic CNS diseases.
• Relies on strategic partnerships, such as with UT Southwestern Medical Center, to leverage scientific expertise and accelerate pipeline development.
• Future revenue generation is anticipated through the potential regulatory approval and commercialization of its gene therapy products, targeting orphan disease markets.
• Secures funding through equity financing and potentially non-dilutive grants or milestone payments from collaborations.

What Industry Does TSHA Operate In?

Taysha Gene Therapies operates within the highly specialized and rapidly evolving biotechnology industry, specifically focusing on gene therapy for rare central nervous system (CNS) disorders. This segment of the healthcare sector is characterized by significant scientific innovation, high research and development costs, and substantial regulatory hurdles. The broader gene therapy market is experiencing robust growth driven by advancements in genetic understanding and delivery technologies, offering transformative potential for previously untreatable diseases. Taysha's niche in monogenic CNS diseases positions it to address severe, often pediatric, conditions with limited or no existing therapies, such as giant axonal neuropathy and Rett syndrome. The competitive landscape includes both established pharmaceutical companies with gene therapy divisions and numerous smaller, specialized biotech firms. Success in this industry is heavily dependent on clinical trial outcomes, intellectual property protection, and strategic partnerships. Taysha's collaboration with The University of Texas Southwestern Medical Center provides a competitive edge by leveraging academic research and expertise in a field where scientific leadership is paramount.

Who Are TSHA's Key Customers?

• Patients diagnosed with rare monogenic diseases of the central nervous system, such as giant axonal neuropathy, Rett syndrome, CLN1 disease, SLC13A5 Deficiency, and GM2 gangliosidosis.
• Healthcare providers, including neurologists, geneticists, and specialized medical centers, who would prescribe and administer the gene therapies.
• Potentially, national healthcare systems and private insurers who would cover the costs of these specialized and high-value treatments.
• Patient advocacy groups and foundations focused on rare neurological disorders, who often play a role in supporting clinical trials and treatment access.

Wall Street analysts project Taysha Gene Therapies, Inc. revenue of about $2.0M for fiscal 2026, with EPS near $-0.46. The estimate reflects 8 contributing analysts.

Taysha Gene Therapies, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 4.5% below estimates on average.

Taysha Gene Therapies, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 11.97 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Taysha Gene Therapies, Inc. stands at -56.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -31.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 17.76 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.3%, the inverse of the P/E and a quick read on earnings relative to price.

Taysha Gene Therapies, Inc. (TSHA) Valuation Context

Valued at $1.95B, TSHA is classified as a small-cap stock. Relative to its peer group, TSHA's quantitative score of 21/100 is below the peer average of 90/100.

Company Profile

Taysha Gene Therapies, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Dallas, US. The company is led by CEO Sean Nolan. TSHA has traded publicly since 2020.

TSHA Financials

TSHA Latest News

TSHA Analyst Consensus

TSHA MoonshotScore

Common Questions About TSHA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources